ストックスクリーナーアプリを入手
1.93
1.03%
-0.02
プレマーケット:
1.93
前日終値:
$1.95
開ける：
$1.97
24時間の取引高:
4.76M
Relative Volume:
0.60
時価総額：
$632.84M
収益：
$4.41M
当期純損益:
$-67.85M
株価収益率:
-8.5474
EPS:
-0.2258
ネットキャッシュフロー:
$-57.15M
1週間 パフォーマンス:
+3.21%
1か月 パフォーマンス:
-17.17%
6か月 パフォーマンス:
+19.88%
1年 パフォーマンス:
+195.47%
1日の値動き範囲:
$1.88
$2.01
1週間の範囲:
$1.71
$2.01
52週間の値動き範囲:
$0.64
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.93 | 632.84M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 110.81B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 78.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 42.71B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | 開始されました | Canaccord Genuity | Buy |
| 2026-03-11 | 開始されました | Oppenheimer | Outperform |
| 2024-10-15 | 開始されました | Maxim Group | Buy |
| 2023-03-01 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 開始されました | Mizuho | Buy |
| 2022-06-15 | 再開されました | ROTH Capital | Buy |
| 2022-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 開始されました | Noble Capital Markets | Outperform |
| 2021-06-11 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-05-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
すべてを表示
Ocugen Inc (OCGN) 最新ニュース
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen Inc. (OCGN): One of the popular penny stocks on Robinhood - MSN
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen, Inc. reports 31 percent drop in GA lesion growth with OCU410 medium dose in phase 2 trial - Traders Union
[SCHEDULE 13G] Ocugen, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Ocugen (OCGN) up 2.9% since last earnings report: Can it continue? - MSN
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
OCGN Forecast, Price Target & Analyst Ratings | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen's Financial Lifeline Fuels High-Stakes Gene Therapy Push - AD HOC NEWS
Ocugen (OCGN) price target increased by 11.11% to 10.20 - MSN
Ocugen Stock Receives 'Moderate Buy' Rating from Analysts - National Today
Ocugen, Inc. (NASDAQ:OCGN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
OCU410 shows nearly double treatment effect over approved therapies, Ocugen, Inc. asserts - Traders Union
Ocugen's Gene Therapy Ambitions Fueled by Clinical and Financial Milestones - AD HOC NEWS
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Benzinga
Ocugen falls after 12-month data from mid-stage trial for GA therapy - MSN
Ocugen Secures Financial Runway as Gene Therapy Pipeline Accelerates - AD HOC NEWS
Ocugen (OCGN) price target increased by 11.43% to 11.37 - MSN
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial - MyChesCo
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Pharma News: Will Ocugen Inc stock recover after earningsTreasury Yields & Community Consensus Picks - baoquankhu1.vn
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Aug Macro: Is Ocugen Inc undervalued by DCF analysisWeekly Stock Summary & Proven Capital Preservation Tips - baoquankhu1.vn
Ocugen (OCGN) has a healthy cash position for 2026 - MSN
Q1 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
Q4 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress - Yahoo Finance
Ocugen, Inc. (OCGN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Wall Street Zen Downgrades Ocugen (NASDAQ:OCGN) to Sell - MarketBeat
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - investing.com
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Hennion & Walsh Asset Management Inc. Invests $1.36 Million in Ocugen, Inc. $OCGN - MarketBeat
Director Zhang Junge exercises 194,134 Ocugen (OCGN) options, lifts direct stake to 1.36M shares - Stock Titan
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - The Globe and Mail
OCGN Finishes Initial Participant Registration for Key Stargardt Disease Trial - bitget.com
Ocugen completes enrollment in Stargardt disease gene therapy trial By Investing.com - za.investing.com
Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program - Sahm
Ocugen Achieves Key Enrollment Target in Stargardt Disease Gene Therapy Trial - AD HOC NEWS
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
$Ocugen (OCGN.US)$ - Moomoo
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease - Ocugen, Inc.
Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease - Ophthalmology Times
Ocugen (OCGN) Completes Dosing in Key Clinical Trial for Stargar - gurufocus.com
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of Ocu410st for Stargardt Disease - marketscreener.com
Ocugen completes enrollment in Stargardt disease gene therapy trial - Investing.com
Ocugen Announces Early Completion of Dosing in Phase 2/3 - GlobeNewswire
Block Trades: What is the next catalyst for Ocugen IncEarnings Recap Report & Real-Time Market Trend Scan - baoquankhu1.vn
Ocugen, Inc. targets 100s of mutations with gene therapies to address 132 billion dollar vision loss burden - Traders Union
Ocugen Inc (OCGN) 財務データ
収益
当期純利益
現金流量
EPS
0.45%
0.77%
大文字化:
|
ボリューム (24 時間):